A new computational drug repurposing method using established disease–drug pair knowledge

N Saberian, A Peyvandipour, M Donato, S Ansari… - …, 2019 - academic.oup.com
Motivation Drug repurposing is a potential alternative to the classical drug discovery
pipeline. Repurposing involves finding novel indications for already approved drugs. In this …

A new computational drug repurposing method using established disease-drug pair knowledge.

N Saberian, A Peyvandipour, M Donato… - Bioinformatics (Oxford …, 2019 - europepmc.org
Results We validated our framework by showing that the proposed method incorporating
distance metric learning technique can retrieve FDA-approved drugs for their approved …

[HTML][HTML] A new computational drug repurposing method using established disease–drug pair knowledge

N Saberian, A Peyvandipour, M Donato, S Ansari… - …, 2019 - ncbi.nlm.nih.gov
Results We validated our framework by showing that the proposed method incorporating
distance metric learning technique can retrieve FDA-approved drugs for their approved …

A new computational drug repurposing method using established disease–drug pair knowledge.

N Saberian, A Peyvandipour, M Donato… - …, 2019 - search.ebscohost.com
Motivation Drug repurposing is a potential alternative to the classical drug discovery
pipeline. Repurposing involves finding novel indications for already approved drugs. In this …

A new computational drug repurposing method using established disease–drug pair knowledge

N Saberian, A Peyvandipour, M Donato, S Ansari… - …, 2019 - academic.oup.com
Motivation Drug repurposing is a potential alternative to the classical drug discovery
pipeline. Repurposing involves finding novel indications for already approved drugs. In this …

A new computational drug repurposing method using established disease-drug pair knowledge

N Saberian, A Peyvandipour… - Bioinformatics …, 2019 - pubmed.ncbi.nlm.nih.gov
Motivation Drug repurposing is a potential alternative to the classical drug discovery
pipeline. Repurposing involves finding novel indications for already approved drugs. In this …